These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
636 related articles for article (PubMed ID: 32245699)
21. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related]
22. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076 [TBL] [Abstract][Full Text] [Related]
23. Identification of Somatically Acquired Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788 [TBL] [Abstract][Full Text] [Related]
24. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
25. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Watkins JA; Irshad S; Grigoriadis A; Tutt AN Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514 [TBL] [Abstract][Full Text] [Related]
26. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related]
27. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. Cook SA; Tinker AV BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302 [TBL] [Abstract][Full Text] [Related]
29. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Talens F; Jalving M; Gietema JA; Van Vugt MA Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306 [TBL] [Abstract][Full Text] [Related]
32. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594 [TBL] [Abstract][Full Text] [Related]
33. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
34. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
35. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085 [TBL] [Abstract][Full Text] [Related]
36. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant. Saito A; Tanioka M; Hirata M; Watanabe T; Odaka Y; Shimoi T; Sudo K; Noguchi E; Ishikawa M; Yonemori K Cancer Treat Res Commun; 2022; 32():100587. PubMed ID: 35696850 [TBL] [Abstract][Full Text] [Related]
37. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885 [TBL] [Abstract][Full Text] [Related]
38. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
39. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer. Blanc-Durand F; Yaniz-Galende E; Llop-Guevara A; Genestie C; Serra V; Herencia-Ropero A; Klein C; Berton D; Lortholary A; Dohollou N; Desauw C; Fabbro M; Malaurie E; Bonichon-Lamaichhane N; Dubot C; Kurtz JE; de Rauglaudre G; Raban N; Chevalier-Place A; Ferron G; Kaminsky MC; Kramer C; Rouleau E; Leary A Gynecol Oncol; 2023 Apr; 171():106-113. PubMed ID: 36868112 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]